Pharmaceutical Regulation

The U.S. Food and Drug Administration (FDA) has once again issued a warning to pharmaceutical giant Novo Nordisk regarding misleading advertising practices for its prescription drugs, underscoring persistent regulatory concerns over promotional claims in the highly scrutinized pharmaceutical market. This latest admonition, directed at the Danish company’s U.S. operations, highlights the FDA’s ongoing vigilance in […]